araag2/HINT huggingface dataset:
Clinical trial NCT01236404 (phase 1/phase 2, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: single subcutaneous dose (part a) of pb1023 or placebo (0.9% nacl), multiple (four weekly) subcutaneous injections (part b) of pb1023 or placebo (0.9% nacl)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males or post menopausal or surgically sterile females age 18-75 years of age
             inclusive.

          -  Diagnosed with T2DM for > or = 6 months with HbA1c > or = 6.0% but < or = 9.0% while
             taking stable doses of one oral antihyperglycemic agent but < or = 8.5% when taking
             two oral antihyperglycemic agents for up to a maximum of 3 months prior to screening.

          -  Fasting Plasma glucose between 115 mg/dL and 269 mg/dL.

          -  Fasting C-peptide of > or = 0.8 ng/mL.

          -  BMI < or = 40 kg/m2.

          -  Otherwise stable health except for T2DM.

        Exclusion Criteria:

          -  Currently taking a non-oral antihyperglycemic agent.

          -  Have taken a PPARg agonist within 90 days of screening.

          -  Known allergy to an approved or investigational GLP-1 receptor analog/agonist.

          -  Unstable cardiovascular disease as defined in clinical protocol.

          -  History, symptoms or signs of pancreatitis or severe gastrointestinal disease.

          -  Personal or family history of medullary thyroid tumors history of Multiple Endocrine
             Neoplasia Syndrome Type 2.

          -  Poor glucose control as defined in clinical protocol.

          -  Clinically significant renal and/or hepatic dysfunction as defined in clinical
             protocol.

          -  Absolute requirement for corticosteroids or received systemic steroids within 90 days
             prior to PB1023 administration.

          -  Pregnant or lactating females.

          -  Known history or active alcohol or drug abuse within 12 months prior to screening.

          -  Positive for HIV, Hepatitis B surface antigen or Hepatitis C antibodies.

          -  Participating in any other study within 30 days prior to screening.

          -  Other medical or psychiatric condition which in the opinion of the investigator would
             place the subject at increased risk.
Clinical trial NCT01290549 (phase 1, status: completed)
Conditions: non-hodgkins lymphoma, chronic lymphocytic leukemia
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, C91.11, C91.12, C91.10
Drugs: polatuzumab vedotin, rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Life expectancy of at least 12 weeks

          -  History of one of the following histologically-documented hematologic malignancy for
             which no effective standard therapy exists: indolent non Hodgkin's lymphoma (NHL),
             Grade 3b follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell
             lymphoma (MCL), or chronic lymphocytic leukemia (CLL)

          -  All participants (NHL and B-cell chronic lymphocytic leukemia [B-CLL]) must have at
             least one bi-dimensionally measurable lesion

          -  For all men or women of childbearing potential (unless surgically sterile): use of
             adequate methods of contraception such as oral contraceptives, intrauterine device, or
             barrier method of contraception in conjunction with spermicidal jelly

        Exclusion Criteria:

          -  Prior use of any monoclonal antibody or antibody-drug conjugate within 4 weeks before
             Cycle 1, Day 1

          -  Treatment with radiotherapy, any chemotherapeutic agent, or treatment with any other
             investigational anti-cancer agent within 2 weeks prior to Cycle 1, Day 1. Adverse
             events from any previous treatments must be resolved or stabilized prior to Cycle 1,
             Day 1, except for neuropathy

          -  Completion of autologous stem cell transplant within 100 days prior to Cycle 1, Day 1

          -  Prior allogeneic stem cell transplant
Clinical trial NCT00137436 (phase 1/phase 2, status: completed)
Conditions: prostatic neoplasms
ICD codes: B38.81, N42.31, Z87.430, N40.0, N40.1
Drugs: docetaxel, prednisone, su011248
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate

          -  Patients must have progressive hormone-refractory prostate cancer (HRPC): patients
             must have undergone primary hormone treatment (e.g. orchiectomy or gonadotropin
             releasing hormone analog with or without antiandrogens). For patients who received
             antiandrogen therapy, disease progression must have been determined after antiandrogen
             discontinuation

          -  Progressive disease based on either non-measurable disease and an elevated PSA OR
             measurable disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

        Exclusion Criteria:

          -  Prior thalidomide, anti-vascular endothelial growth factor (VEGF) therapy, VEGF
             receptor inhibitor, platelet-derived growth factor (PDGF) receptor inhibitor or
             anti-angiogenic treatment of any kind including investigational therapy

          -  Prior chemotherapy

          -  Uncontrolled pain at baseline, impending complication from bone metastasis (fracture
             and/or compression) and/or presence of urinary obstruction (urinary retention,
             hydronephrosis)

          -  History of cardiac dysfunction, QT interval corrected for heart rate (QTc) >450 msec

          -  Central Nervous System (CNS) involvement
Clinical trial NCT02083315 (phase 1, status: completed)
Conditions: pain, acute
ICD codes: G89.12, G89.18, G89.11, G89.3
Drugs: trv130 1.5 mg, trv130 3 mg, trv130 4.5 mg, morphine 10 mg, placebo
SMILES: [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent

          -  Healthy adult males age 18 - 50 years, BMI 19-32 kg/m2

          -  Acceptable duration of cold pain test results at screening

        Exclusion Criteria:

          -  Clinically significant medical illness or physical exam findings

          -  Active dermatological conditions or skin trauma on the non-dominant hand, or
             peripheral vascular disease

          -  Partial blindness, keratoconus, nystagmus or any other ophthalmic condition which
             could interfere with pupillometry

          -  Use of tobacco or nicotine within 6 months prior to screening

          -  History of recent (within 6 months) drug or alcohol abuse, as defined in DSM-IV-TR
Clinical trial NCT00405548 (phase 1/phase 2, status: completed)
Conditions: left ventricular diastolic dysfunction
ICD codes: I47.2, I49.01, I49.02, I49.3, Q21.0, I47.0, I50.1
Drugs: bnp (nesiritide), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with ejection fraction of greater than 50% with moderate or severe diastolic
             dysfunction as assessed by Doppler echocardiography

          -  No signs or symptoms of congestive heart failure and who have not been hospitalized
             for heart failure

        Exclusion criteria:

          -  Myocardial Infarction (MI) within 3 months of screening

          -  Unstable angina within 14 days of screening, or any evidence of myocardial ischemia

          -  Significant valvular stenosis, hypertrophic, restrictive or obstructive
             cardiomyopathy, constrictive pericarditis, primary pulmonary hypertension, or biopsy
             proven active myocarditis

          -  Severe congenital heart diseases

          -  Sustained ventricular tachycardia or ventricular fibrillation within 14 days of
             screening

          -  Second or third degree heart block without a permanent cardiac pacemaker

          -  Stroke within 3 months of screening, or other evidence of significantly compromised
             central nervous system (CNS) perfusion

          -  Total bilirubin of > 1.5 mg/dL or other liver enzymes > 1.5 times the upper limit of
             normal (mg/dL = milligrams per deciliter)

          -  Serum creatinine of > 3.0 mg/dL

          -  Serum sodium of < 125 mEq/dL or > 160 mEq/dL (milliequivalents per deciliter)

          -  Serum potassium of < 3.5 mEq/dL or > 5.0/dL

          -  Serum digoxin level of > 2.0 ng/ml (nanograms per milliliter)

          -  Systolic pressure of < 85 mm Hg (millimeters of mercury)

          -  Hemoglobin < 10 gm/dl (grams per deciliter)
Clinical trial NCT00084058 (phase 1/phase 2, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: lopinavir/ritonavir, saquinavir
SMILES: OC(=O)[C@@H]1CCCN1, [H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(N)=O)NC(=O)C1=NC3=C(C=CC=C3)C=C1)[C@@H](C2)C(=O)NC(C)(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  HIV infected

          -  HIV RNA viral load greater than 5,000 copies/ml

          -  At least 6 months of continuous therapy with a protease inhibitor (PI) prior to study
             entry

          -  No change in antiretroviral therapy since genotypic resistance testing

          -  Genotypic resistance testing indicating a primary protease mutation at position 32,
             47, 48, 50, 82, or 84 and at least three other mutations in positions 10, 20, 24, 30,
             32, 33, 36, 46, 47, 48, 50, 53, 54, 71, 73, 77, 82, 84, or 90 OR phenotypic resistance
             testing, within 6 months of screening while on a failing regimen, indicating at least
             a fivefold increase in LPV as compared to wild type HIV

          -  Parent or legal guardian willing to provide informed consent

          -  If sexually active, agree to use acceptable methods of contraception

          -  Have a telephone, pager, or other method of reliable communication with study staff

          -  Able and willing to swallow study medications

        Exclusion Criteria:

          -  Any drug toxicity greater than Grade 3 at screening

          -  Certain abnormal laboratory values

          -  Acute opportunistic or serious bacterial infection requiring treatment

          -  Chemotherapy for active cancer

          -  Any significant diseases (other than HIV infection) that may, in the opinion of the
             investigator, interfere with the study

          -  Require certain medications

          -  History of heart problems

          -  Family history of prolonged QTc-Interval Syndrome or prolonged QTc-interval at study
             entry

          -  Pregnancy or breastfeeding
Clinical trial NCT00303251 (phase 1/phase 2, status: completed)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: tki258
SMILES: CN1CCN(CC1)C1=CC=C2N=C(NC2=C1)C1=C(N)C2=C(NC1=O)C=CC=C2F
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of locally advanced or metastatic melanoma (American Joint
             Committee on Cancer [AJCC] stage IIIB, IIIC or IV) that is refractory to standard
             therapy or for which no curative standard therapy exists.

          -  Measurable disease

          -  Must be eighteen years of age or older

          -  Must meet baseline laboratory requirements

          -  ECOG performance status 0 or 1

          -  Adults of reproductive potential must agree to use effective contraception or be
             sterile

        Exclusion Criteria:

          -  Concurrent therapy with any other investigational agent

          -  Uncontrolled central nervous system metastases

          -  Impaired cardiac function or clinically significant cardiac disease

          -  Received

               -  chemotherapy, targeted therapy or monoclonal antibody therapy ≤4 weeks

               -  biological therapy or immunotherapy (therapeutic or diagnostic) ≤2 weeks

               -  an investigational agent (therapeutic or diagnostic) ≤4 weeks prior to starting
                  study drug or has not recovered from side effects of such therapy

          -  Received any hematopoietic colony-stimulating factor (e.g., G-CSF, GM-CSF) ≤ 2 weeks
             prior to starting study drug. Erythropoietin is allowed.

          -  Has undergone major surgery ≤ 2 weeks prior to starting study drug or has not
             recovered from side effects of such surgery.

          -  Malabsorption syndrome or uncontrolled gastrointestinal symptoms such as nausea,
             diarrhea, vomiting

          -  Pregnant or breast feeding women

          -  History of another primary malignancy that is currently clinically significant or
             currently requires active intervention.

          -  Chronic anticoagulation therapy with full strength aspirin, Coumadin, or heparin.

          -  History of thromboembolic or cerebrovascular events within the last 12 months.

          -  History of rectal bleeding, bloody vomit, or spitting up blood within the last 3
             months.

          -  Known diagnosis of HIV infection (HIV testing is not mandatory)

          -  Use of ketoconazole, erythromycin, carbamazepine, phenobarbital, phenytoin, rifampin,
             St. John's wort and quinidine is prohibited.

          -  Other severe, acute, or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or
             study-drug administration or may interfere with the interpretation of study results
             and, in the judgment of the investigator, make the patient inappropriate for this
             study
Clinical trial NCT00499239 (phase 1/phase 2, status: terminated)
Conditions: non-hodgkin's lymphoma, chronic lymphocytic leukemia, multiple myeloma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, C91.11, C91.12, C91.10, C90.01, C90.02, C90.00
Drugs: gs-9219
SMILES: CCOC(=O)[C@H](C)NP(=O)(COCCN1C=NC2=C(NC3CC3)N=C(N)N=C12)N[C@@H](C)C(=O)OCC
Reason stopped: 
    unacceptable safety profile
  
Eligibility criteria:

        Inclusion Criteria:

          -  Relapsed or refractory CLL, NHL or MM

          -  ECOG Performance Status of 0, 1, or 2

          -  Adequate organ function (protocol defined)

          -  ECG without evidence of clinically significant ventricular arrhythmias

        Exclusion Criteria:

          -  AIDS-related lymphoma

          -  Subjects with NHL who present exclusively with non-measurable lesions

          -  Subjects with MM who have non-secretory and/or non-measurable disease

          -  Recent anticancer therapy (chemotherapy, radiotherapy, and/or biotherapy)within four
             weeks prior to starting treatment

          -  Evidence of pulmonary fibrosis

          -  Other concurrent malignancy

          -  Uncontrolled concurrent illness

          -  Receiving chronic, systemically administered steroids

          -  Known hypersensitivity to nucleoside analogues
Clinical trial NCT00560391 (phase 1, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: dasatinib, 70 mg + lenalidomide, 15 mg + dexamethasone, 40 mg, dasatinib, 70 mg + lenalidomide, 20 mg + dexamethasone, 40 mg, dasatinib, 100 mg + lenalidomide, 20 mg + dexamethasone, 40 mg, dasatinib, 100 mg + lenalidomide, 25 mg + dexamethasone, 40 mg, dasatinib, 140 mg + lenalidomide, 25 mg + dexamethasone, 40 mg
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Able to provide written informed consent

          -  Men and women age ≥ 18 years

          -  Confirmed diagnosis of multiple myeloma (MM) with measurable disease assessed within 1
             month prior to treatment initiation

          -  Evidence of relapsed or refractory disease and at least one prior therapy for MM

          -  Eastern Cooperative Oncology Group Scale (ECOG) Performance Status of 0 - 2

          -  Last MM treatment at least 21 days prior to treatment initiation• Bone marrow
             transplant (BMT) at least 3 months prior to treatment initiation

          -  Required baseline hematology and chemistry parameters

          -  Resolution of acute toxicity due to prior therapy to Grade <2 per National Cancer
             Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding

          -  Men whose sexual partners are women of child bearing potential (WOCBP) or WOCBP who
             are unwilling or unable to use an acceptable method to avoid pregnancy for the entire
             study period and for at least one month (4 weeks) before and for at least one month (4
             weeks) after the last dose of study medication.

          -  Clinically significant cardiac disease (New York Heart Association [NYHA] Class III or
             IV)

          -  Abnormal corrected QT interval using Fridericia's formula (QTcF) interval prolonged (>
             450 msec)

          -  Medications that are generally considered to have a risk of causing "Torsades de
             Pointes"

          -  Malabsorption syndrome or uncontrolled gastrointestinal toxicities

          -  Clinically significant pleural effusion in the previous 12 months or current ascites

          -  Clinically-significant coagulation or platelet function disorder

          -  Dementia, chronic medical or psychiatric condition, or laboratory abnormality

          -  Other severe, acute, or chronic medical or psychiatric condition or laboratory
             abnormality, serious uncontrolled medical disorder or active infection

          -  Intolerance to dasatinib and/or lenalidomide

          -  Subjects with a history of severe rash, hypersensitivity reaction or anaphylaxis
             related to prior thalidomide treatment
Clinical trial NCT00610571 (phase 1, status: completed)
Conditions: glioblastoma, gliosarcoma, anaplastic astrocytoma
ICD codes: C84.67, C84.77, C84.7A, C84.60, C84.70, C84.62, C84.66
Drugs: oral topotecan and temodar
SMILES: CN1N=NC2=C(N=CN2C1=O)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histology: GBM, AA or grade 3 or greater WHO astrocytic, oligodendroglial or mixed
             glial tumors which were initially diagnosed by histologic exam of biopsy/resection

          -  Age: > or equal to 18 years

          -  Performance Status: Karnofsky Performance Status > or equal to 60% at study entry.

          -  Renal Function: Serum creatinine < 1.5 mg/dl or creatinine clearance > 60 ml/dL.

          -  Hematologic Status: The following baseline studies will be required before entry:
             total granulocyte count > or equal to 1000/microliter; platelet count >
             100,000/microliter

          -  Hepatic Function: Serum SGOT & total bilirubin < or equal to 2.5 times ULN.

          -  Note: All lab parameters must have been obtained within 1 week of registration

          -  Consent: Signed informed consent, approved by IRB, will be obtained prior to
             initiating treatment

          -  Corticosteroids: For patients currently on corticosteroids, patients should be on
             stable dose for 1 week prior to study entry, if clinically possible.

          -  Prior Therapy: Interval of at least 2 weeks between prior surgical resection or prior
             radiotherapy (XRT) or 1 week from completion of chemotherapy and all toxicities are <
             or equal to grade 1 & enrollment on this protocol unless there is unequivocal evidence
             of progressive disease.

          -  Patients with Reproductive Potential: Patients must agree to practice effective birth
             control measures while on study and for 2 months after completing therapy

        Exclusion Criteria:

          -  Pregnant or breast feeding women or women or men with reproductive potential not
             practicing adequate contraception. This therapy may be associated with potential
             toxicity to the fetus or child that exceeds minimum risks necessary to meet health
             needs of mother

          -  Active infection requiring intravenous antibiotics

          -  Prior failure with either topotecan or temozolomide
Clinical trial NCT01033227 (phase 1/phase 2, status: terminated)
Conditions: sickle cell disease
ICD codes: D57.1, D57.20, D57.212, D57.219, D57.211, D57.213, D57.218
Drugs: sodium nitrite injection, usp
SMILES: ON=O
Reason stopped: 
    low enrollment
  
Eligibility criteria:

        Inclusion Criteria:

        Subjects meeting all of the following criteria will be considered for admission to the
        study:

          1. Male or female subject aged between 8 and 23 years of age; only patients up to the age
             of 23 will be studied at Childrens Hospital Los Angeles

          2. Electrophoretic diagnosis of sickle cell disease;

          3. Sudden onset of acute pain involving >=1 sites typical of vaso-occlusive crisis
             (Vaso-occlusive crisis is defined as acute, severe pain in the extremities, chest,
             abdomen, or back that can not be explained by other complications of sickle cell
             disease or by a cause other than sickle cell disease.);

          4. Severe pain requiring parenteral analgesics and hospitalization.

          5. Informed consent obtained from a legal representative or from subjects 18 years of age
             or older before enrollment;

          6. Being willing and able to be followed for at least 30 days for evaluation.

        Exclusion Criteria:

        Subjects presenting with any of the following will not be included in the study:

          1. Clinically significant bleeding;

          2. Current drug abuse or participation in methadone program;

          3. Episode of pain requiring hospitalization within 2 weeks prior to current admission;

          4. Other complications of sickle cell disease including cerebrovascular accident,
             pulmonary hypertension, or seizure;

          5. Pregnancy (confirmed by a serum human chorionic gonadotropin pregnancy test) or breast
             feeding;

          6. Blood pressure less than 25th percentile for the subject's age and sex on admission or
             at the time of screening;

          7. Methemoglobinemia >3%;

          8. Anemia with hemoglobin level less than 6 g/dL;

          9. Red blood cell G6PD deficiency, by laboratory testing prior to enrollment;

         10. History of allergy to nitrites or allergy to other substances characterized by dyspnea
             and cyanosis;

         11. Treatment with allopurinol, a medication that could interfere with nitrite metabolism,
             within the past 30 days before screening;

         12. Treatment with any investigational drug within the past 30 days;

         13. Significant acute or chronic concomitant diseases (including renal, hepatic,
             cardiovascular, pulmonary, or oncologic disease, sepsis, pulmonary edema, pulmonary
             embolism) that would be inconsistent with survival for at least 6 months;

         14. Any subject judged by the clinical investigator or study manager to be inappropriate
             for the study.